Key points
- Loss from ordinary activities increased by 19.2% to $1,981,169
- No dividends paid, recommended, or declared
- Successful IND application submission for MagSense® HER2 Imaging Agent
- Placement completed raising $3.75 million
- Material uncertainty exists regarding going concern
Full summary
Imagion Biosystems Ltd reported a half-year loss of $1,981,169, up from $1,661,455 in the previous period. The company did not pay, recommend, or declare any dividends. The loss was driven by research and development expenses, professional fees, and general expenses. The company successfully submitted an Investigational New Drug (IND) application for its MagSense® HER2 Imaging Agent to the U.S. FDA, which was approved, allowing the Phase 1b/2 clinical trial to proceed. Imagion also completed a placement raising $3.75 million, with the second tranche subject to shareholder approval. The financial statements include a material uncertainty regarding the company's ability to continue as a going concern due to net current liabilities and net liabilities as of June 30, 2026.
Guidance
Loss from ordinary activities after tax: $1,981,169 (half-year 2026)
Outlook
Imagion expects to initiate the clinical trial Part A as early as September 2026 and anticipates reporting results in Q1 2027.